Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives

Abstract

A compound of Formula I in free or salt or solvate form, where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

1 - 21 . (canceled) 
     
     
         22 . A method of treating a disease mediated by the blockade of an epithelial sodium channel in a patient in need thereof, said method comprising:
 administering to said patient a therapeutically effective amount of a compound selected from the group consisting of   
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       and the pharmaceutically acceptable salts thereof. 
     
     
         23 . The method according to  claim 22 , wherein the compound is selected from the group consisting of 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
       and the pharmaceutically acceptable salts thereof. 
     
     
         24 . The method according to  claim 22 , wherein the compound is selected from the group consisting of 
       
         
           
           
               
               
           
         
       
       and the pharmaceutically acceptable salts thereof. 
     
     
         25 . The method according to  claim 22 , wherein the compound is 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         26 . The method according to  claim 22 , wherein the compound is 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         27 . The method according to  claim 22 , wherein the compound is 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         28 . The method according to  claim 22 , wherein the compound is 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         29 . The method according to  claim 22 , wherein the compound is 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         30 . The method according to  claim 22 , wherein the compound is 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         31 . The method according to  claim 22 , wherein the disease mediated by the blockade of an epithelial sodium channel is an inflammatory or allergic condition. 
     
     
         32 . The method according to  claim 31 , wherein the inflammatory or allergic condition is cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia, or keratoconjunctivitis sire. 
     
     
         33 . The method according to  claim 32 , wherein the inflammatory or allergic condition is cystic fibrosis, chronic obstructive pulmonary disease, or asthma. 
     
     
         34 . The method according to  claim 32 , wherein the inflammatory or allergic condition is cystic fibrosis, or chronic obstructive pulmonary disease. 
     
     
         35 . The method according to  claim 32 , wherein the inflammatory or allergic condition is cystic fibrosis.